AstraZeneca said on Thursday a late-stage trial showed its medicine for a rare disease that causes accumulation of copper in the body was three times more successful in helping remove deposits from tissues compared with standard care.
The treatment, developed by the drugmaker’s recently acquired Alexion rare diseases unit, was being tested for Wilson disease, a genetic condition in which the body’s ability to remove excess copper is compromised.
For the latest headlines, follow our Google News channel online or via the app.
The experimental oral medicine taken once-daily could provide a less invasive option for patients who are typically given treatments which involve injecting a metal removing solution into the blood or zinc therapy.
“As we advance this first innovation in Wilson disease treatment in more than 30 years, we will continue to follow these patients long term to further assess clinical impact on disease symptoms,” Alexion Chief Executive Officer Marc Dunoyer said.
Copper build-up can cause liver disease and psychiatric or neurological symptoms, such as personality changes, tremors, and difficulty in walking, swallowing, or talking.
The study met the main goal of improvement in the daily mean copper mobilized from tissues over a period of 48 weeks. The treatment has been given an “Orphan Drug” status in the United States and European Union to help speed up development.
AstraZeneca’s new antibody treatment therapy prevents COVID-19: StudyTrial data from AstraZeneca on Friday raised the prospect of a new treatment to prevent COVID-19 beyond vaccines, giving hope in particular for people ... Coronavirus
Combining AstraZeneca and mRNA COVID-19 vaccines is 88 percent effective: StudyCombining AstraZeneca’s COVID-19 vaccine with a second dose from either Pfizer-BioNTech or Moderna’s jab provides “good protection,” Denmark’s State ... Coronavirus
AstraZeneca vaccine should be halted for over-60s: EMACountries should avoid giving the AstraZeneca coronavirus vaccine to people over 60 in addition to younger age groups, the head of the EU drug ... Coronavirus
AstraZeneca’s antibody treatment fails to protect patients exposed to COVID-19Anglo-Swedish drugmaker AstraZeneca said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing ... Coronavirus